PedvaxHIB® — Competitive Intelligence Brief

PedvaxHIB® (PedvaxHIB®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Conjugate vaccine. Area: Immunology / Infectious Disease.

marketed Conjugate vaccine Haemophilus influenzae type b polyribosylribitol phosphate (PRP) capsular polysaccharide Immunology / Infectious Disease Biologic

Target snapshot

PedvaxHIB® (PedvaxHIB®) — GlaxoSmithKline. PedvaxHIB is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) by presenting the bacterial polysaccharide capsule linked to a protein carrier.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PedvaxHIB® TARGET	PedvaxHIB®	GlaxoSmithKline	marketed	Conjugate vaccine	Haemophilus influenzae type b polyribosylribitol phosphate (PRP) capsular polysaccharide
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
pneumococcal conjugate 13 valent vaccine	pneumococcal conjugate 13 valent vaccine	University of Siena	marketed	Conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (13 serotypes)
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate	Meningococcal Polysaccharide Diphtheria Toxoid Conjugate	Sanofi Pasteur, a Sanofi Company	marketed	Conjugate vaccine	Neisseria meningitidis polysaccharide capsule
Streptococcus pneumoniae serotype 3	Streptococcus pneumoniae serotype 3	University of Oxford	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae serotype 3 capsular polysaccharide
Hib conjugate vaccine	Hib conjugate vaccine	Public Health England	marketed	Conjugate vaccine	Haemophilus influenzae type b polysaccharide capsule
NeisVac-C®	NeisVac-C®	Merck Sharp & Dohme LLC	marketed	Meningococcal conjugate vaccine	Neisseria meningitidis serogroup C polysaccharide capsule

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Conjugate vaccine class)

1. GlaxoSmithKline · 26 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 6 drugs in this class
3. CanSino Biologics Inc. · 3 drugs in this class
4. MCM Vaccines B.V. · 3 drugs in this class
5. Beijing Minhai Biotechnology Co., Ltd · 3 drugs in this class
6. Wyeth is now a wholly owned subsidiary of Pfizer · 2 drugs in this class
7. PT Bio Farma · 2 drugs in this class
8. LG Life Sciences · 2 drugs in this class
9. Walvax Biotechnology Co., Ltd. · 2 drugs in this class
10. Heinrich-Heine University, Duesseldorf · 1 drug in this class